Product Description
mRNA-1944 is being developed with financial support from Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense. mRNA-1944 is the first development candidate from the Company’s systemic therapeutics modality to start clinical testing and utilizes the same lipid nanoparticle (LNP) formulation as the Company’s rare disease program for methylmalonic acidemia (mRNA-3704). CHKV-24, the antibody encoded by mRNA-1944, was isolated from B cells of a patient with potent immunity against chikungunya infection by scientists at Vanderbilt University Medical Center. mRNA-1944 is composed of two mRNAs that encode respectively for the heavy and light chains of CHKV-24 that are formulated within Moderna’s proprietary LNP technology for systemic intravenous injection. (Sourced from: https://www.sec.gov/Archives/edgar/data/1682852/000119312519243385/d796420dex992.htm)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Chikungunya Fever
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| mRNA-1944-P101 | P1 |
Completed |
Chikungunya Fever |
2021-06-07 |